CIZ Cizzle Biotechnology Holdings Plc

TIDMCIZ

RNS Number : 0618M

Cizzle Biotechnology Holdings PLC

17 September 2021

17 September 2021

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")

New Research Agreement with the University of York for Cancer Tests

Cizzle Biotechnology, the UK based diagnostics developer , is pleased to announce that it has entered into a new research agreement with the University of York for the development and validation of molecular tools with potential applications in cancer diagnosis and therapy.

The Company's wholly owned subsidiary Cizzle Biotechnology Limited was a spin out from the University of York based on original research and development undertaken in laboratories at the University, under the direction of Professor Dawn Coverley. The new agreement extends that relationship and provides seconded staff and access to the University's state of the art research facilities to support reagent generation work in collaboration with our recently announced Contract Research Organisation (CRO) partner Fairjouney Biologics.

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said: "We are thrilled to be able to cement our long-standing relationship with the University of York, a member of the Russell Group of research-intensive universities and one of the world's premier institutions for inspirational and life-changing research. This new agreement will provide valuable additional resource and capability for developing our blood test for the early detection of lung cancer, and potentially other forms of cancer ."

Enquiries:

 
 Cizzle Biotechnology Holdings     Via IFC Advisory 
  plc 
 Allan Syms (Executive Chairman) 
 
 
 Allenby Capital Limited    +44(0) 20 33285656 
 John Depasquale 
 Alex Brearley 
 
 
 Novum Securities Limited    +44(0) 20 7399 9400 
 Colin Rowbury 
  Jon Bellis 
 
 
 IFC Advisory Limited    +44(0) 20 3934 6630 
 Tim Metcalfe 
 Florence Chandler 
 

About the Company

Cizzle Biotechnology is developing a blood test for the early detection of a majority of the different forms of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early stage lung cancer.

For more information please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRLFMATMTJBBAB

(END) Dow Jones Newswires

September 17, 2021 01:59 ET (05:59 GMT)

Cizzle Biotechnology (LSE:CIZ)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Cizzle Biotechnology (LSE:CIZ)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024